Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
MedImmune LLC |
---|---|
Information provided by: | MedImmune LLC |
ClinicalTrials.gov Identifier: | NCT00263783 |
To determine the safety profile of single and multiple doses of MEDI522 in patients with refractory solid tumors.
Condition | Intervention | Phase |
---|---|---|
Cancer |
Drug: MEDI-522 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment |
Official Title: | Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors |
Estimated Enrollment: | 24 |
Study Start Date: | March 2001 |
Estimated Study Completion Date: | July 2003 |
Ages Eligible for Study: | 18 Years to 18 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | MI-CP065 |
Study First Received: | December 8, 2005 |
Last Updated: | January 26, 2007 |
ClinicalTrials.gov Identifier: | NCT00263783 |
Health Authority: | United States: Food and Drug Administration |